Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Yutaka Endo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7187-0124; OpenAlex author ID A5041646818. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers

Papers 17

  1. Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… First author DOI 10.1245/s10434-025-17661-7↗
  2. ASO Author Reflections: Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02)-… First author DOI 10.1245/s10434-025-17876-8↗
  3. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. First author DOI 10.1002/cam4.7459↗
  4. Association between social determinants of health and delayed postoperative adjuvant therapy among patients undergoing resection of pancreatic cancer. Co-author DOI 10.1002/jso.27571↗
  5. Association between quality metric adherence and overall survival among patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.04.043↗
  6. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  7. Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review. Co-author DOI 10.3390/cancers16091632↗
  8. Association between the Environmental Quality Index and Textbook Outcomes Among Medicare Beneficiaries Undergoing Surgery for Early-Stage Pancreatic Adenocarci… Co-author DOI 10.1007/s11605-023-05757-y↗
  9. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Co-author DOI 10.1245/s10434-023-13230-y↗
  10. The Impact of Medicaid Expansion on Early-Stage Pancreatic Adenocarcinoma at High- Versus Low-Volume Facilities. Co-author DOI 10.1245/s10434-023-13810-y↗
  11. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methyla… Co-author DOI 10.1007/s00432-021-03541-6↗
  12. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant thera… Co-author DOI 10.1002/cam4.3044↗
  13. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Co-author DOI 10.1111/cas.14425↗
  14. Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. Co-author DOI 10.1038/s41379-019-0291-z↗
  15. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… Co-author DOI 10.1186/s12957-019-1687-4↗
  16. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/mco.2019.1883↗
  17. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Co-author DOI 10.1038/bjc.2017.479↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 12 shared papers, 2018–2025 · strength 2.01
  2. Yuko Kitagawa · 10 shared papers, 2018–2025 · strength 1.64
  3. Yuta Abe · 8 shared papers, 2018–2025 · strength 1.01
  4. Muhammad Musaab Munir · 5 shared papers, 2023–2024 · strength 0.97
  5. Timothy Michael Pawlik · 5 shared papers, 2023–2024 · strength 0.97
  6. Yutaka Nakano · 7 shared papers, 2018–2025 · strength 0.92
  7. Koichi Aiura · 4 shared papers, 2019–2025 · strength 0.67
  8. Mary E. Dillhoff · 3 shared papers, 2023–2024 · strength 0.62
  9. Yohei Masugi · 5 shared papers, 2019–2024 · strength 0.54
  10. Chanza Fahim Shaikh · 3 shared papers, 2023 · strength 0.50
  11. Henrique Araujo Lima · 3 shared papers, 2023 · strength 0.50
  12. Zorays Moazzam · 3 shared papers, 2023 · strength 0.50
  13. Zayed Rashid · 2 shared papers, 2024 · strength 0.47
  14. Shutaro Hori · 4 shared papers, 2019–2024 · strength 0.45
  15. Yutaka Takigawa · 2 shared papers, 2024–2025 · strength 0.40
  16. Junichi Matsui · 2 shared papers, 2024–2025 · strength 0.40
  17. Yuko Kitagawa · 2 shared papers, 2024 · strength 0.37
  18. Aslam M. Ejaz · 2 shared papers, 2023–2024 · strength 0.36
  19. Erryk Katayama · 2 shared papers, 2023 · strength 0.32
  20. Sojun Hoshimoto · 1 shared paper, 2025 · strength 0.22
  21. Yosuke Uematsu · 1 shared paper, 2025 · strength 0.22
  22. Muhammad Muntazir Mehdi Khan · 1 shared paper, 2024 · strength 0.21
  23. Diamantis I. Tsilimigras · 1 shared paper, 2024 · strength 0.21
  24. Gaku Shimane · 1 shared paper, 2024 · strength 0.19
  25. Masayuki Tanaka · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.